#United States #New York #Investor Rights #Bronstein Gewirtz Grossman #GeneDx Holdings

Bronstein, Gewirtz & Grossman LLC Initiates Class Action Lawsuit Against GeneDx Holdings Corp

On June 7, 2026, Bronstein, Gewirtz & Grossman LLC, a prominent law firm focusing on investor rights, announced the filing of a class action lawsuit against GeneDx Holdings Corp (NASDAQ: WGS) and several of its executives. This lawsuit seeks to obtain damages for alleged violations of federal securities laws on behalf of individuals and entities who acquired GeneDx securities from April 16, 2025, through May 4, 2026, during what is defined as the ‘Class Period.’

Key Allegations in the Class Action

The class action complaint outlines several significant claims against the defendants. It is alleged that throughout the Class Period, they made misleading statements and omitted vital information regarding GeneDx's operations, financial prospects, and business strategies. Specific claims include:
1. Misleading Claims about Fabric Genomics: The company allegedly misled its investors concerning the role and importance of Fabric Genomics in its operations.
2. Margin Decrease: Due to the inadequately disclosed operations, the margins of the company are reportedly on track to decline, contrary to previous claims.
3. Reimbursement Rates: Investors were allegedly misled about the sustainability of the company’s average reimbursement rates, which were touted as being more resilient than they actually are.
4. Overall Misrepresentation: The culmination of these misrepresentations led to the conclusion that the optimistic statements made by the defendants lacked a reasonable basis and were materially false or misleading.

What This Means for Investors

For individuals who invested in GeneDx during the outlined Class Period, the implications of this lawsuit are substantial. The legal representation by Bronstein, Gewirtz & Grossman LLC is conducted on a contingency fee basis. This means that the firm only gets reimbursed for expenses and legal fees if a successful recovery is achieved, ensuring that individuals don’t face upfront costs in their pursuit of justice.

If any investor intends to participate in this case, they are encouraged to act swiftly, as the deadline to request appointment as lead plaintiff is set for August 3, 2026. The firm actively encourages those who suffered financial losses to consider joining the case, highlighting that participation doesn’t necessitate serving as the lead plaintiff to reap potential recovery benefits.

Why Choose Bronstein, Gewirtz & Grossman LLC?

Bronstein, Gewirtz & Grossman LLC has established itself as a leading law firm in the realm of securities fraud. The firm has a robust track record of recouping hundreds of millions of dollars for investors through class actions and shareholder derivative suits. According to Peretz Bronstein, founder of the firm, their focus lies in restoring investor capital and maintaining corporate accountability to uphold the integrity of the financial marketplace.

Individuals looking to learn more or join the class action can visit their official website, bgandg.com/WGS, or contact Peretz Bronstein or Nathan Miller directly at the firm’s office. This legal action represents an important avenue for investors who seek compensation and accountability from GeneDx Holdings Corp. as the unfolding case will continue to be monitored closely.

Conclusion

As this class action lawsuit unfolds, it stands not only as a means for potential recovery for affected investors but also as a vital reminder of the importance of transparency and honesty in corporate communication. Key stakeholders are advised to stay informed on developments related to GeneDx and the lawsuit as it progresses.